Extrait

to investigate whether long-term treatment with rosuvastatin 20 mg compared with placebo will decrease the rate (based on time to first event after randomization) of major cardiovascular events (combined endpoint of cardiovascular death, stroke, myocardial infarction, unstable angina, or arterial revascularization) among individuals with low LDL C (<130 mg/dL [3.36 mmol/L]) who are at high vascular risk on the basis of an enhanced inflammatory response, as determined by elevated levels of CRP (equal to or exceeding 2.0 mg/L).

Critère d'inclusion

• healthy subjects without prior history of MI, stroke or arterial revascularization who, on initial screening, are found to have LDL.C levels below 130 mg/dL (3.36 mmol/L) and CRP levels equal to or exceeding 2.0 mg/L

Liens

• euctr
• euctr
• ictrp
• ictrp
• ictrp
• ictrp
• euctr
• euctr
• euctr
• ictrp